Ultimaster™ Family Clinical Program
2
true
References
References
A comprehensive clinical program
3
A remarkable 16 CE marked indications
3
Consistent good sa​​fety* data at 1 year from controlled clinical trial <sup>4</sup> and routine clinical practice<sup>8</sup>
3
neutrals-100
Sustained long-term sa​fety* from controlled clinical trial4​
3
1-month DAPT for H​​BR patients
3
​​MASTER DAPT is the largest multi-center randomized controlled study to confirm the safety and efficacy of abbreviated DAP in HBR patients following stenting procedures with Ultimaster Family DES.
References
text
Stojkovic S et al. Fundam Clin Pharmacol 2014;29:95–105;
text
Barbato E et al. EuroIntervention 2015;11:541–8;
text
Saito S et al. Eur Heart J 2014;35:2021–31;
text
Wijns W et al. EuroIntervention 2018;14:e343–51;
text
Valdes-Chavarri M et al. EuroIntervention 2019;14:e1836-42;
text
Chevalier B et al. Circ Cardiovasc Interv 2017;10e004801;
text
Mohamed et al. EuroIntervention 2020;16:603-612
text
Cimci M et al. Heart 2022;108:1310-1318.
text
Frigoli E et al. Am Heart J 2019;209:97-105
text
Valgimigli M et al. N Engl J Med 2021;385:1643-1655
text
Kozuma K et al. Circ J 2020;85:19-26
text
Hioki H et al.J Cardiol 2021;78:107-113​​
Featured products
3